Giuseppe Procopio, MD
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Fondazione IRCCS istituto Nazionale dei Tumori di Milano
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Giuseppe Procopio, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06528483 · Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerFondazione IRCCS Istituto Nazionale dei Tumori, Milano · not yet recruiting · Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm · principal investigator
- Ph2NCT06302569 · Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaGiuseppe Procopio · recruiting · Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary Carcinoma · principal investigator
- N/ANCT05782400 · Multiomics Approach in Metastatic Clear Renal Cell CarcnomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano · active not recruiting · Metastatic Clear Cell Renal Carcinoma · principal investigator
- N/ANCT04891055 · Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · unknown · Metastatic Renal Cell Carcinoma · principal investigator
- Ph2NCT04462445 · Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIbFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Metastatic Renal Cell Carcinoma · principal investigator
- Ph2NCT03463681 · A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Metastatic Renal Cell Carcinoma · principal investigator
- Ph2NCT03456401 · Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · terminated · Renal Cancer Cell · study chair
- Ph2NCT03354884 · caBozantinib in cOllectiNg ductS Renal Cell cArcInomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Collecting Duct Carcinoma (Kidney) · principal investigator
- Ph3NCT02535351 · Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers DiscoveryFondazione IRCCS Istituto Nazionale dei Tumori, Milano · terminated · Clear-cell Metastatic Renal Cell Carcinoma · principal investigator
- Ph2NCT01444807 · Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the MetastasesFondazione IRCCS Istituto Nazionale dei Tumori, Milano · unknown · Metastatic Renal Cell Carcinoma · study chair
- Ph2NCT00609401 · Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)Italian Trial in Medical Oncology · completed · Metastatic Disease, Renal Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.